Genetically defined favourable adiposity is not associated with a clinically meaningful difference in clinical course in people with type 2 diabetes but does associate with a favourable metabolic profile.
dc.contributor.author | Heald, AH | |
dc.contributor.author | Martin, S | |
dc.contributor.author | Fachim, H | |
dc.contributor.author | Green, HD | |
dc.contributor.author | Young, KG | |
dc.contributor.author | Malipatil, N | |
dc.contributor.author | Siddals, K | |
dc.contributor.author | Cortes, G | |
dc.contributor.author | Tyrrell, J | |
dc.contributor.author | Wood, AR | |
dc.contributor.author | Beaumont, RN | |
dc.contributor.author | Frayling, TM | |
dc.contributor.author | Donn, R | |
dc.contributor.author | Narayanan, RP | |
dc.contributor.author | Ollier, W | |
dc.contributor.author | Gibson, M | |
dc.contributor.author | Yaghootkar, H | |
dc.date.accessioned | 2022-01-28T14:10:02Z | |
dc.date.issued | 2021-01-27 | |
dc.date.updated | 2022-01-28T13:12:06Z | |
dc.description.abstract | AIMS: Change in weight, HbA1c , lipids, blood pressure and cardiometabolic events over time is variable in individuals with type 2 diabetes. We hypothesised that people with a genetic predisposition to a more favourable adiposity distribution could have a less severe clinical course/progression. METHODS: We involved people with type 2 diabetes from two UK-based cohorts: 11,914 individuals with GP follow-up data from the UK Biobank and 723 from Salford. We generated a 'favourable adiposity' genetic score and conducted cross-sectional and longitudinal studies to test its association with weight, BMI, lipids, blood pressure, medication use and risk of myocardial infarction and stroke using 15 follow-up time points with 1-year intervals. RESULTS: The 'favourable adiposity' genetic score was cross-sectionally associated with higher weight (effect size per 1 standard deviation higher genetic score: 0.91 kg [0.59,1.23]) and BMI (0.30 kg/m2 [0.19,0.40]), but higher high-density lipoprotein (0.02 mmol/L [0.01,0.02]) and lower triglycerides (-0.04 mmol/L [-0.07, -0.02]) in the UK Biobank at baseline, and this pattern of association was consistent across follow-up. There was a trend for participants with higher 'favourable adiposity' genetic score to have lower risk of myocardial infarction and/or stroke (odds ratio 0.79 [0.62, 1.00]) compared to those with lower score. A one standard deviation higher score was associated with lower odds of using lipid-lowering (0.91 [0.86, 0.97]) and anti-hypertensive medication (0.95 [0.91, 0.99]). CONCLUSIONS: In individuals with type 2 diabetes, having more 'favourable adiposity' alleles is associated with a marginally better lipid profile long-term and having lower odds of requiring lipid-lowering or anti-hypertensive medication in spite of relatively higher adiposity. | en_GB |
dc.description.sponsorship | Diabetes UK | en_GB |
dc.description.sponsorship | European Research Council | en_GB |
dc.description.sponsorship | Medical Research Council | en_GB |
dc.description.sponsorship | Research England | en_GB |
dc.format.extent | e14531- | |
dc.format.medium | Print-Electronic | |
dc.identifier.citation | Vol. 38, No. 9, article e14531 | en_GB |
dc.identifier.doi | https://doi.org/10.1111/dme.14531 | |
dc.identifier.grantnumber | 17/0005594 | en_GB |
dc.identifier.grantnumber | 323195 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/128638 | |
dc.identifier | ORCID: 0000-0001-8746-0947 (Martin, Susan) | |
dc.identifier | ORCID: 0000-0002-5105-184X (Green, Harry D) | |
dc.identifier | ORCID: 0000-0003-2570-3864 (Young, Katherine G) | |
dc.identifier | ORCID: 0000-0002-9256-6065 (Tyrrell, Jessica) | |
dc.identifier | ORCID: 0000-0003-1726-948X (Wood, Andrew R) | |
dc.identifier | ORCID: 0000-0003-0750-8248 (Beaumont, Robin N) | |
dc.identifier | ScopusID: 57156164500 (Beaumont, Robin N) | |
dc.identifier | ORCID: 0000-0001-9672-9477 (Yaghootkar, Hanieh) | |
dc.language.iso | en | en_GB |
dc.publisher | Wiley/Diabetes UK | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/33501652 | en_GB |
dc.rights | © 2021 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK | en_GB |
dc.subject | BMI | en_GB |
dc.subject | HbA1c | en_GB |
dc.subject | ectopic fat | en_GB |
dc.subject | favourable adiposity genetic score | en_GB |
dc.subject | metabolic profile | en_GB |
dc.subject | myocardial infarction | en_GB |
dc.subject | stroke | en_GB |
dc.subject | type 2 diabetes | en_GB |
dc.title | Genetically defined favourable adiposity is not associated with a clinically meaningful difference in clinical course in people with type 2 diabetes but does associate with a favourable metabolic profile. | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2022-01-28T14:10:02Z | |
dc.identifier.issn | 0742-3071 | |
exeter.article-number | ARTN e14531 | |
exeter.place-of-publication | England | |
dc.description | This is the final version. Available from Wiley via the DOI in this record. | en_GB |
dc.description | DATA AVAILABILITY STATEMENT We used patient-level data which was fully anonymised prior to analysis. Any requests for access to the Salford data should be made to Dr Adrian Heald. | en_GB |
dc.identifier.eissn | 1464-5491 | |
dc.identifier.journal | Diabetes Medicine | en_GB |
dc.relation.ispartof | Diabet Med, 38(9) | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2021-01-21 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2021-01-27 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2022-01-28T13:57:06Z | |
refterms.versionFCD | VoR | |
refterms.panel | A | en_GB |
refterms.dateFirstOnline | 2021-01-27 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2021 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK